

Hong Jiang,^a Xiang-Shan Wang,^{b*} Mei-Mei Zhang,^b Yu-Ling Li^b and Da-Qing Shi^b^aThe Key Laboratory of Biotechnology for Medical Plants of Jiangsu Province, Xuzhou Normal University, Xuzhou 221116, People's Republic of China, and ^bDepartment of Chemistry, Xuzhou Normal University, Xuzhou 221116, People's Republic of ChinaCorrespondence e-mail:
xswang1974@yahoo.com

Key indicators

Single-crystal X-ray study
T = 173 K
Mean $\sigma(\text{C}-\text{C})$ = 0.003 Å
R factor = 0.029
wR factor = 0.076
Data-to-parameter ratio = 12.5For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


2-Amino-4-(2-chlorophenyl)-7,7-dimethyl-1-(4-methylphenyl)-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carbonitrile

The title compound, $\text{C}_{25}\text{H}_{24}\text{ClN}_3\text{O}$, was synthesized by the reaction of 2-chlorophenylmethylidenemalononitrile and 3-(4-tolylamino)-5,5-dimethylcyclohex-2-enone in the presence of triethylbenzylammonium chloride in an aqueous medium. All bond lengths and angles are normal. In the crystal structure, intermolecular $\text{N}-\text{H}\cdots\text{O}$ hydrogen bonds link the molecules into chains extending in the [101] direction.

Received 17 February 2006

Accepted 21 February 2006

Comment

Quinolines and their derivatives exhibit diverse pharmacological activities, such as cholinesterase (Isomae *et al.*, 2002), antiplasmodial (Beagley *et al.*, 2003), cytotoxic (Ma *et al.*, 2004), functional (Denton *et al.*, 2005) and antibacterial (Fokialakis *et al.*, 2002) activities. To avoid the inherent disadvantages of many organic solvents, such as toxicity and non-stability, we are working under a new environmentally friendly procedure for the synthesis of the above-mentioned compounds. Specifically, we have focused our attention on the use of water as a reaction medium following Breslow & Rideout (1980), who rediscovered the use of water as a solvent in organic chemistry. We report here the crystal structure of the title compound, (I).In (I), all bond lengths and angles (Table 1) are normal. The N1/C1–C5 ring is not planar, adopting a boat conformation (Fig. 1). Atoms C3 and N1 deviate from the basal plane defined by atoms C1/C2/C4/C5 by 0.200 (2) and 0.073 (1) Å, respectively. Similar distortions were observed in 7,7-dimethyl-2-(4-bromophenyl)-4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline (Shi *et al.*, 2002) and 3,3,6,6-tetramethyl-9-(4-chlorophenyl)-10-(4-methylphenyl)-1,2,3,4,5,6,7,8,9,10-decahydroacridine-1,8-dione (Wang *et al.*, 2003). The C4/C5/C7–C10 ring adopts a half-chair conformation; atom C9 deviates from the mean plane of the remaining atoms by 0.630 (2) Å. A




Figure 1
A view of (I), showing the atom-numbering scheme and with displacement ellipsoids drawn at the 50% probability level.




Figure 2
The molecular packing, viewed down the *b* axis, showing the intermolecular hydrogen bonds as dashed lines.

similar conformation has been found in the structure of 7,7-dimethyl-2-amino-3-cyano-4-(3,4-methylenedioxyphenyl)-5-oxo-5,6,7,8-tetrahydro-4*H*-benzo[*b*]pyran (Wang *et al.*, 2002). The benzene rings make a dihedral angle of 9.0 (1)°.

In the crystal structure, intermolecular N—H...O hydrogen bonds (Table 2) link the molecules into chains extending in the [101] direction (Fig. 2).

Experimental

The title compound, (I), was prepared by the reaction of 2-chlorophenylmethylidenemalononitrile (2 mmol) and 3-(4-tolylamino)-5,5-dimethylcyclohex-2-enone (2 mmol) in the presence of triethylbenzylammonium chloride (0.1 g) in water at 363 K for 8 h (yield 98%; m.p. 525–527 K). Crystals of (I) suitable for X-ray diffraction were obtained by slow evaporation of a dimethylformamide solution. Elemental analysis calculated: C 71.85, H 5.79, N 10.05%; found: C 71.73, H 6.01, N 9.98%. ¹H NMR (DMSO-*d*₆, δ, p.p.m.): 0.73 (*s*, 3H, CH₃), 0.89 (*s*, 3H, CH₃), 1.73 (*d*, *J* = 16.0 Hz, 1H, CH), 1.90 (*d*, *J* = 16.0 Hz, 1H, CH), 2.19 (*d*, *J* = 16.8 Hz, 2H, CH₂), 4.47 (*s*, 1H, CH), 5.33 (*s*, 2H, NH₂), 7.04–7.48 (*m*, 8H, ArH).

Crystal data

C₂₅H₂₄N₂ClN₃O
M_r = 417.92
 Monoclinic, *Cc*
a = 19.541 (2) Å
b = 9.0199 (8) Å
c = 14.8424 (16) Å
 β = 124.628 (2)°
V = 2152.7 (4) Å³
Z = 4

D_x = 1.290 Mg m⁻³
 Mo K α radiation
 Cell parameters from 4284 reflections
 θ = 3.3–25.3°
 μ = 0.20 mm⁻¹
T = 173 (2) K
 Block, yellow
 0.59 × 0.50 × 0.30 mm

Data collection

Rigaku Mercury diffractometer
 ω scans
 Absorption correction: multi-scan (Jacobson, 1998)
T_{min} = 0.892, *T_{max}* = 0.943
 10014 measured reflections
 3434 independent reflections

3389 reflections with *I* > 2 σ (*I*)
R_{int} = 0.016
 θ_{\max} = 25.3°
h = -23 → 21
k = -10 → 10
l = -15 → 17

Refinement

Refinement on *F*²
R[*F*² > 2 σ (*F*²)] = 0.029
wR(*F*²) = 0.076
S = 1.05
 3434 reflections
 275 parameters
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0474P)^2 + 0.7163P]$
 where $P = (F_o^2 + 2F_c^2)/3$
 $(\Delta/\sigma)_{\max} < 0.001$
 $\Delta\rho_{\max} = 0.20 \text{ e \AA}^{-3}$
 $\Delta\rho_{\min} = -0.22 \text{ e \AA}^{-3}$
 Absolute structure: Flack (1983),
 with 1478 Friedel pairs
 Flack parameter: -0.04 (5)

Table 1

Selected geometric parameters (Å, °).

N1—C1	1.392 (2)	C2—C3	1.524 (2)
N1—C5	1.396 (2)	C3—C4	1.514 (2)
C1—C2	1.360 (2)	C4—C5	1.355 (2)
C1—N1—C5	119.95 (14)	C4—C3—C2	108.62 (14)
C2—C1—N1	120.82 (15)	C5—C4—C3	123.57 (15)
C1—C2—C3	123.42 (15)	C4—C5—N1	121.15 (15)
C5—N1—C1—C2	6.5 (2)	C2—C3—C4—C5	15.2 (2)
N1—C1—C2—C3	6.6 (3)	C3—C4—C5—N1	-4.5 (3)
C1—C2—C3—C4	-16.2 (2)		

Table 2
Hydrogen-bond geometry (Å, °).

$D-H\cdots A$	$D-H$	$H\cdots A$	$D\cdots A$	$D-H\cdots A$
$N2-H2B\cdots O1^i$	0.88	2.36	2.937 (2)	123

Symmetry code: (i) $x + \frac{1}{2}, -y + \frac{3}{2}, z + \frac{1}{2}$.

The H atoms were positioned geometrically and refined as riding, with $C-H = 0.95-1.00$ Å and $N-H = 0.88$ Å, and with $U_{iso}(H) = 1.2-1.5U_{eq}$ of the parent atom.

Data collection: *CrystalClear* (Rigaku, 1999); cell refinement: *CrystalClear*; data reduction: *CrystalStructure* (Rigaku/MSC, 2003); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997a); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997a); molecular graphics: *SHELXTL* (Sheldrick, 1997b); software used to prepare material for publication: *SHELXL97*.

The authors thank the Natural Science Foundation (grant No. 04 KJB150139) of the Education Committee of Jiangsu Province and the Natural Science Foundation (grant No. 05XLB30) of Xuzhou Normal University for financial support.

References

- Beagley, P., Blackie, M. A. L., Chibale, K., Clarkson, C., Meijboom, R., Moss, J. R., Smith, P. & Su, H. (2003). *Dalton Trans.* pp. 3046–3051.
- Breslow, R. & Rideout, D. C. (1980). *J. Am. Chem. Soc.* **102**, 7816–7817.
- Denton, T. T., Zhang, X. & Cashman, J. R. (2005). *J. Med. Chem.* **48**, 224–239.
- Flack, H. D. (1983). *Acta Cryst.* **A39**, 876–881.
- Fokialakis, N., Magiatis, P., Chinou, L., Mitaku, S. & Tillequin, F. (2002). *Chem. Pharm. Bull.* **50**, 413–414.
- Isomae, K., Ishikawa, M., Ohta, M., Ogawa, Y., Hasegawa, H., Kohda, T. & Kamei, J. (2002). *Jpn J. Pharm.* **88**, 206–212.
- Jacobson, R. (1998). Private communication to the Rigaku Corporation, Tokyo, Japan.
- Ma, Z., Hano, Y., Nomura, T. & Chen, Y. (2004). *Bioorg. Med. Chem. Lett.* **14**, 1193–1196.
- Rigaku (1999). *CrystalClear*. Rigaku Corporation, Tokyo, Japan.
- Rigaku/MSC (2003). *CrystalStructure*. Rigaku/MSC, 9009 New Trails Drive, The Woodlands, TX 77381-5209, USA.
- Sheldrick, G. M. (1997a). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.
- Sheldrick, G. M. (1997b). *SHELXTL*. Version 5.1. Bruker AXS Inc., Madison, Wisconsin, USA.
- Shi, D. Q., Wang, X. S., Tu, S. J., Yao, C. S. & Wang, C. S. (2002). *Chin. J. Struct. Chem.* **21**, 410–413.
- Wang, X., Shi, D. & Tu, S. (2003). *Acta Cryst.* **E59**, o1139–o1140.
- Wang, X. S., Shi, D. Q., Tu, S. J., Yao, C. S. & Wang, Y. C. (2002). *Chin. J. Struct. Chem.* **21**, 146–149.